FindTrial
Sign In

The verification and optimization of the risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults

The verification and optimization of the risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035379
Enrollment
Unknown
Registered
2020-08-09
Start date
2020-08-10
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xp11.2 translocation renal cell carcinoma

Interventions

Gold Standard:immunohistochemical (IHC) assay for TFE3 combined with fluorescence in situ hybridisation (FISH) assay
Index test:renal tumor tissue

Sponsors

Affiliated Drum Tower Hospital, Medical School of Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as renal tumor, aged 19-80 years; 2. Patients will undertake radical nephrectomy or partial nephrectomy; 3. Patients with full preoperative inspection records; 4. Patients evaluated as high-risk by Xp11.2 translocation renal cell carcinoma risk-scoring system or evaluated as positive in secondary indicators.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete medical history; 2. Patients with severe underlying diseases.

Design outcomes

Primary

MeasureTime frame
symptoms(gross hematuria);CT (intratumoral calcification);unenhanced CT density;CT enhancement pattern;—

Secondary

MeasureTime frame
MRI T1 unenhanced signal;—

Countries

China

Contacts

Public ContactWeidong Gan

Affiliated Drum Tower Hospital, Nanjing University

gwd@nju.edu.cn+86 13305186699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026